Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs
Molecules · 18.07.2025 · 30 (14) · 3026
DOI: 10.3390/molecules30143026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 18.07.2025. Verfasst von Junmin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Biology and Food Science, Shangqiu Normal University, Shangqiu 476000, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Molecular Targeted Therapy, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Henan Province, Key Scientific Research Project in Universities of Henan Province.
Abstract (Originalsprache)
Breast cancer is one of the most common malignant tumors among women, which seriously threatens women’s health. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, characterized by poor prognosis, is an aggressive phenotype accounting for 15–20% of all kinds of breast cancers. Therefore, it has attracted great interest among researchers in discovering targeted therapy drugs countering HER2, and they have been considered as the pivotal therapeutic regimen for HER2-positive breast cancer patients. Nowadays, large progress has been achieved in HER2-targeted drugs, and this review categorizes them into four types according to the drug action mode, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), and bispecific antibodies (bsAbs). The progress of HER2-targeted drugs reflects the discovery of drug targets, the screening of drug compounds, and the modification of antibodies, which offer diverse medical options and better therapeutic benefits for individual patients. In detail, we focus on the indication, administration, efficacy, strengths, and challenges of HER2-targeted drugs, concerning approved drugs and clinical trials. This review aims to provide significant references for the targeted therapeutic regimen and a more precise treatment strategy for HER2-positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biology and Food Science, Shangqiu Normal University, Shangqiu 476000, China.
- Basic Medical Department, Nanyang Medical College, Nanyang 473001, China.
ORCID-Profile: Junmin Li, Yakun Fang, Chunmei Zhang, Bingbing Ma, Yanan Ding, Chuanxin Shi, Qingfeng Zhou
Förderung
- Natural Science Foundation of Henan Province
- Key Scientific Research Project in Universities of Henan Province
Zitieren
APA
Li, J., Li, X., Fu, R., Fang, Y., Zhang, C., Ma, B., Ding, Y., Shi, C., & Zhou, Q. (2025). Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs. Molecules, 30(14), 3026. https://doi.org/10.3390/molecules30143026
Vancouver
Li J, Li X, Fu R, Fang Y, Zhang C, Ma B, et al. Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs. Molecules. 2025;30(14):3026. doi:10.3390/molecules30143026
BibTeX
@article{Li2025,
author = {Li, Junmin and Li, Xue and Fu, Ruixin and Fang, Yakun and Zhang, Chunmei and Ma, Bingbing and Ding, Yanan and Shi, Chuanxin and Zhou, Qingfeng},
title = {Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs},
journal = {Molecules},
year = {2025},
volume = {30},
number = {14},
pages = {3026},
doi = {10.3390/molecules30143026}
}
EUVIMED